(Note: For PDF File Swipe To The End Of Article)

Introduction to Malaria

Malaria is a potentially life-threatening infectious disease caused by parasites of the genus Plasmodium. It is transmitted primarily through the bite of infected female Anopheles mosquitoes. Malaria is one of the most important parasitic diseases affecting humans and remains a major public-health problem in many tropical and subtropical regions. Although malaria is preventable and curable, delayed diagnosis and treatment can allow uncomplicated infection to progress rapidly to severe disease and death.

The disease is particularly important in regions where mosquito transmission is common, including large parts of sub-Saharan Africa, South and Southeast Asia, parts of Latin America, and several other tropical areas. The risk of infection varies according to geography, climate, mosquito populations, parasite prevalence, season, access to preventive measures, and the level of immunity within the population.

Malaria is caused by several species of Plasmodium. The five species known to cause malaria in humans are Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, and Plasmodium knowlesi. Among these, P. falciparum is particularly dangerous because it can produce severe disease rapidly, while P. vivax is an important cause of malaria in many regions outside sub-Saharan Africa.

The clinical presentation of malaria can vary considerably. Some patients develop mild fever, chills, headache, body aches, weakness, nausea, and vomiting, while others may develop severe anemia, jaundice, respiratory distress, kidney injury, seizures, altered consciousness, shock, coma, or multiple-organ failure.

One of the major difficulties in recognizing malaria is that its early symptoms can resemble many other febrile illnesses. Fever and headache may initially appear similar to influenza, viral infections, typhoid fever, dengue fever, or other infections. For this reason, malaria should be considered whenever a patient with compatible symptoms has been exposed to an area where malaria transmission occurs.

Prompt laboratory diagnosis is essential. WHO recommends parasite-based confirmation using microscopy or a rapid diagnostic test in suspected cases. Early treatment is especially important for P. falciparum, because untreated infection can progress to severe disease very quickly.

Causative Organisms of Malaria

Malaria is caused by protozoan parasites belonging to the genus Plasmodium. These organisms have a complex life cycle involving both humans and mosquitoes.

Five Plasmodium species are recognized as causes of human malaria:

Plasmodium falciparum
Plasmodium vivax
Plasmodium malariae
Plasmodium ovale
Plasmodium knowlesi

Each species has distinctive biological and clinical characteristics.

P. falciparum is considered the most dangerous species because it can produce severe malaria and death if treatment is delayed. It is particularly prevalent in Africa but is also found in other malaria-endemic regions.

P. vivax is widely distributed and is particularly important outside sub-Saharan Africa. One of its distinctive characteristics is its ability to form dormant liver stages called hypnozoites. These dormant parasites can reactivate later and cause relapses.

P. malariae can produce a more chronic infection and may persist in the body for prolonged periods.

P. ovale can also form dormant liver stages and therefore may cause relapsing infection.

P. knowlesi is primarily associated with parts of Southeast Asia and can sometimes produce severe disease.

Correct identification of the infecting species is clinically important because treatment differs according to parasite species, geographic origin, drug resistance patterns, and whether dormant liver-stage parasites need to be eliminated.

The Malaria Parasite

The malaria parasite has a complex life cycle that alternates between the mosquito and human host.

The infection begins when an infected female Anopheles mosquito bites a human and injects parasites called sporozoites into the bloodstream.

The sporozoites rapidly travel to the liver. They enter hepatocytes and undergo a period of development and multiplication.

After multiplication within liver cells, parasites are released into the bloodstream as merozoites. These merozoites invade red blood cells.

The blood-stage parasites pass through several developmental forms, including ring forms, trophozoites, and schizonts. Eventually, infected red blood cells rupture and release new merozoites, which infect additional red blood cells.

This repeated cycle of red-cell invasion and rupture contributes substantially to the clinical manifestations of malaria, particularly fever and chills.

Some parasites within red blood cells differentiate into sexual forms called gametocytes. These gametocytes can be taken up by another mosquito during a blood meal.

Inside the mosquito, the sexual stages undergo further development, eventually producing new sporozoites that migrate to the mosquito's salivary glands.

The mosquito can then transmit the parasite to another human during a subsequent bite.

Transmission of Malaria

The primary route of malaria transmission is through the bite of an infected female Anopheles mosquito.

Not every mosquito can transmit malaria. The mosquito must first acquire the parasite by feeding on the blood of an infected person. The parasite then develops inside the mosquito before the mosquito becomes capable of transmitting infection.

When the infected mosquito subsequently bites another person, sporozoites enter the person's bloodstream.

Malaria therefore involves a continuous transmission cycle between humans and mosquitoes.

The disease is not normally transmitted through casual contact such as touching, hugging, sharing food, coughing, or being in the same room.

However, malaria can rarely be transmitted through other routes, including contaminated blood products, contaminated needles, and congenital transmission from mother to fetus.

Because transmission depends on mosquitoes, environmental conditions strongly influence malaria prevalence. Temperature, rainfall, humidity, mosquito breeding sites, and seasonal patterns can all affect transmission.

Role of the Anopheles Mosquito

The female Anopheles mosquito plays a central role in malaria transmission.

Female mosquitoes require blood meals to support egg production. During feeding, an infected mosquito can introduce malaria parasites into the human bloodstream.

Mosquitoes generally breed in water. Different Anopheles species prefer different types of breeding environments, including pools, puddles, irrigation areas, and other water-containing locations.

The abundance and behavior of mosquito populations can therefore influence local malaria transmission.

Mosquito-control programs aim to reduce contact between mosquitoes and humans or reduce mosquito populations.

Important approaches include insecticide-treated mosquito nets, indoor residual spraying, environmental management, and other vector-control measures appropriate to local epidemiology.

Geographical Distribution of Malaria

Malaria is primarily associated with tropical and subtropical regions.

The disease burden is particularly high in the WHO African Region, which accounted for approximately 95% of global malaria cases and deaths in 2024. Children under five years accounted for about three-quarters of malaria deaths in that region.

Malaria transmission can also occur in parts of Asia, Latin America, the Middle East, and Oceania.

The geographical distribution of malaria is not static. Changes in climate, land use, mosquito populations, human movement, public-health interventions, and parasite drug resistance can influence transmission patterns.

Travelers from regions without malaria transmission may be particularly vulnerable because they may have little or no acquired immunity.

Risk Factors for Malaria

The most important risk factor is exposure to malaria-transmitting mosquitoes.

People living in or traveling to malaria-endemic regions have an increased risk of infection.

However, the risk of severe disease differs among individuals.

Infants and young children are particularly vulnerable because they have not developed sufficient immunity.

Pregnant women are also at increased risk of malaria-related complications.

People with HIV/AIDS or other conditions affecting immunity may have increased susceptibility to severe infection.

Travelers from non-endemic regions may develop severe disease because they lack partial immunity that can develop after repeated exposure.

Other mobile populations and migrants entering areas of intense transmission may also have increased risk.

The use or non-use of preventive measures, such as insecticide-treated bed nets and appropriate chemoprevention when indicated, also influences risk.

Incubation Period of Malaria

The incubation period refers to the time between infection and the appearance of symptoms.

For many malaria infections, symptoms begin approximately 10–15 days after the infective mosquito bite, although the timing varies according to the parasite species, immune status, and other factors.

However, malaria does not always appear immediately.

Some infections may remain clinically silent for longer periods. Dormant liver-stage parasites associated with P. vivax and P. ovale can reactivate months after the initial infection.

Antimalarial drugs taken for travel prevention can also sometimes delay the appearance of symptoms.

Therefore, a patient presenting with unexplained fever should mention previous travel or residence in malaria-endemic areas even if the exposure occurred weeks or months earlier.

Life Cycle of Malaria Parasite

The malaria life cycle consists of several stages occurring in both humans and mosquitoes.

When an infected mosquito bites a person, sporozoites enter the bloodstream.

The sporozoites travel rapidly to the liver and invade liver cells.

Inside hepatocytes, the parasites multiply. This stage is called the hepatic or exoerythrocytic stage.

The liver cells eventually release merozoites into the bloodstream.

Merozoites invade red blood cells and develop through different stages.

The parasites multiply inside red blood cells, and infected cells eventually rupture.

The released merozoites infect additional red blood cells, producing repeated cycles of infection.

Some parasites develop into gametocytes rather than continuing the asexual blood-stage cycle.

When another mosquito feeds on the infected person, it ingests the gametocytes.

The sexual stage develops inside the mosquito, eventually producing sporozoites.

The sporozoites migrate to the mosquito's salivary glands.

The mosquito is then capable of infecting another human during a subsequent blood meal.

Hepatic Stage of Malaria

The hepatic stage occurs inside liver cells.

After entering the bloodstream, sporozoites reach the liver and invade hepatocytes.

They multiply within these cells before releasing merozoites into the bloodstream.

This stage is particularly important because the patient may not yet have the typical symptoms associated with blood-stage malaria.

In P. vivax and P. ovale, some parasites can remain dormant within liver cells as hypnozoites.

These dormant forms can reactivate later and produce relapses.

This biological characteristic explains why treating the blood-stage infection alone may not always be sufficient for P. vivax or P. ovale.

Erythrocytic Stage of Malaria

The erythrocytic stage occurs within red blood cells and is responsible for most clinical manifestations.

Merozoites invade red blood cells and develop through recognizable stages.

The young parasite is commonly described as the ring form.

It develops into a trophozoite and subsequently into a schizont.

The schizont undergoes further multiplication, producing new merozoites.

Eventually, the infected red blood cell ruptures, releasing merozoites into the circulation.

These newly released parasites infect additional red blood cells.

Repeated cycles of red-cell invasion and rupture contribute to fever, chills, anemia, and other systemic manifestations.

The blood-stage parasite is therefore central to the clinical disease.

Pathophysiology of Malaria

The pathophysiology of malaria is complex and depends strongly on the infecting species.

The disease begins with invasion and multiplication of parasites within the liver, followed by infection of red blood cells.

As infected red blood cells rupture, parasite-derived substances and inflammatory mediators stimulate the immune system.

The release of inflammatory cytokines contributes to fever, chills, malaise, headache, and other systemic symptoms.

Repeated destruction of red blood cells contributes to anemia.

The spleen also becomes involved because it removes infected and damaged red blood cells from circulation.

In P. falciparum infection, infected red blood cells can adhere to vascular endothelium and become sequestered in small blood vessels.

This sequestration can interfere with microvascular blood flow and contribute to tissue hypoxia and organ dysfunction.

When the brain is affected, cerebral malaria may develop.

Severe malaria can therefore involve multiple organs, including the brain, kidneys, lungs, liver, and cardiovascular system.

Fever in Malaria

Fever is one of the most characteristic manifestations of malaria.

The fever results from inflammatory responses associated with parasite development and rupture of infected red blood cells.

A classical malaria attack may involve a sequence of chills, fever, and sweating.

However, patients do not always present with a textbook periodic fever pattern, particularly during the early stages of infection.

The timing of fever may vary according to parasite species and the synchronization of parasite replication.

Therefore, absence of a classic periodic fever pattern does not exclude malaria.

Any unexplained fever in a person with relevant exposure should prompt consideration of malaria.

Clinical Classification of Malaria

Malaria is generally classified into uncomplicated malaria and severe malaria.

Uncomplicated malaria refers to infection without features of severe organ dysfunction or other criteria indicating life-threatening disease.

Severe malaria occurs when infection produces serious complications such as impaired consciousness, seizures, severe anemia, respiratory distress, kidney injury, shock, metabolic abnormalities, jaundice, abnormal bleeding, or other manifestations of organ dysfunction.

The distinction is clinically important because severe malaria requires urgent hospital-based management and parenteral antimalarial treatment.

Symptoms of Uncomplicated Malaria

Early malaria symptoms can be nonspecific.

Common symptoms include:

Fever
Chills
Headache
Sweating
Weakness
Fatigue
Muscle aches
Body aches
Nausea
Vomiting
Abdominal discomfort
Diarrhea
Malaise

Some patients may initially experience only mild symptoms.

This can lead to delayed diagnosis, particularly when malaria is not common in the local population.

A patient may believe that the illness is simply influenza or another viral infection.

In endemic areas, individuals may recognize the symptoms more readily, although presumptive self-treatment without diagnostic confirmation can also create problems.

Laboratory confirmation remains important because malaria symptoms overlap with many other diseases.

Fever and Chills

Fever and chills are among the most recognizable symptoms of malaria.

A patient may experience a sudden feeling of cold accompanied by intense shivering.

This may be followed by a period of high fever.

The fever may then subside with profuse sweating.

These episodes can recur as parasites undergo repeated blood-stage cycles.

However, the classic sequence is not present in every patient.

In particular, patients with early infection or partially treated disease may have irregular fever patterns.

Therefore, clinical suspicion should not depend on identifying a specific fever cycle.

Headache and Body Aches

Headache is a common early symptom of malaria.

Patients may describe generalized headache accompanied by muscle aches, weakness, and fatigue.

These symptoms can make malaria resemble viral respiratory infections or other febrile illnesses.

The severity of headache varies from mild discomfort to significant pain.

When headache occurs together with fever, chills, recent travel to an endemic region, or other suggestive findings, malaria should be considered.

Gastrointestinal Symptoms

Malaria can produce several gastrointestinal manifestations.

Patients may experience:

Nausea
Vomiting
Abdominal pain
Loss of appetite
Diarrhea

These symptoms may sometimes dominate the clinical presentation.

Children may be particularly vulnerable to dehydration when fever, vomiting, and diarrhea occur together.

Gastrointestinal symptoms should therefore be assessed alongside hydration status and other systemic findings.

Physical Examination Findings

Physical findings vary according to disease severity.

A patient with uncomplicated malaria may have fever, sweating, weakness, tachycardia, and an increased respiratory rate.

Splenomegaly may develop because the spleen removes infected and damaged red blood cells.

Hepatomegaly can also occur.

Mild jaundice may be present.

Laboratory findings can include anemia, thrombocytopenia, increased bilirubin, and elevated aminotransferases.

Severe malaria may produce hypotension, altered consciousness, respiratory distress, reduced urine output, jaundice, or other signs of organ dysfunction.

Anemia in Malaria

Anemia is a common complication of malaria.

It develops through several mechanisms.

Infected red blood cells are destroyed during parasite replication.

The spleen also removes infected and damaged red blood cells.

Inflammatory processes may suppress effective red-cell production.

Repeated or severe infection can therefore cause significant anemia.

Severe anemia is particularly dangerous in young children because it can impair oxygen delivery to tissues.

Patients may develop pallor, weakness, fatigue, tachycardia, dizziness, and respiratory distress when anemia becomes severe.

Thrombocytopenia in Malaria

A reduction in platelet count is commonly observed in malaria.

Thrombocytopenia may result from several mechanisms, including increased platelet destruction and sequestration.

Although thrombocytopenia is common, it does not automatically mean that severe bleeding will occur.

However, marked thrombocytopenia together with abnormal bleeding should be treated seriously.

Laboratory evaluation of platelet count can provide useful information during the assessment of a patient with suspected malaria.

Splenomegaly in Malaria

The spleen plays an important role in removing abnormal and infected red blood cells.

Repeated malaria infections can therefore stimulate enlargement of the spleen.

Splenomegaly may be more prominent in individuals who have experienced recurrent infections.

In endemic regions, chronic exposure may produce substantial changes in splenic function and size.

A palpable spleen in a patient with fever and other malaria-compatible findings can therefore provide an important clinical clue, although its absence does not exclude malaria.

Jaundice in Malaria

Jaundice can occur when malaria causes significant hemolysis or liver dysfunction.

The destruction of red blood cells increases bilirubin production.

Severe malaria can also involve hepatic dysfunction.

Mild jaundice may occur in uncomplicated infection, while more pronounced jaundice may be associated with severe disease or other complications.

When jaundice occurs with fever, anemia, altered consciousness, kidney dysfunction, or other severe features, urgent evaluation is required.

Severe Malaria

Severe malaria is a medical emergency.

It can develop when parasites cause extensive tissue and organ dysfunction.

Severe manifestations include:

Impaired consciousness
Coma
Seizures
Severe anemia
Respiratory distress
Acute kidney injury
Reduced urine output
Pulmonary edema
Shock
Metabolic acidosis
Jaundice
Abnormal bleeding
Hypoglycemia

High parasite density can also indicate severe disease.

The presence of any major severe-malaria feature requires urgent hospital management.

Cerebral Malaria

Cerebral malaria is one of the most dangerous complications of P. falciparum infection.

It is characterized by impaired consciousness and neurological dysfunction.

Patients may develop confusion, abnormal behavior, seizures, reduced consciousness, and eventually coma.

Cerebral malaria results from complex interactions between infected erythrocytes, vascular endothelium, inflammatory responses, and impaired microcirculation within the brain.

Children are particularly vulnerable to severe neurological complications in high-transmission settings.

Cerebral malaria requires immediate treatment and intensive supportive care.

Respiratory Complications

Severe malaria can affect the respiratory system.

Patients may develop rapid breathing because of metabolic acidosis.

Pulmonary edema or acute respiratory distress syndrome can occur in severe disease.

Respiratory distress is particularly concerning in children with severe malaria.

A patient with malaria who develops difficulty breathing, increasing respiratory rate, low oxygen saturation, or signs of respiratory failure requires urgent assessment and supportive management.

Kidney Complications

Severe malaria can cause acute kidney injury.

The kidneys may be affected by hemolysis, impaired microcirculation, dehydration, inflammation, and other systemic effects.

Patients may develop reduced urine output, elevated creatinine, electrolyte abnormalities, and fluid disturbances.

Severe kidney injury may require specialized supportive treatment, including renal replacement therapy in appropriate cases.

Kidney dysfunction is one of the important markers of severe malaria.

Hypoglycemia in Malaria

Hypoglycemia can occur in severe malaria.

It may result from increased glucose consumption, impaired hepatic glucose production, prolonged illness, or certain antimalarial treatments.

Hypoglycemia is particularly dangerous because the brain depends heavily on glucose.

Symptoms can include sweating, weakness, confusion, seizures, and altered consciousness.

Because severe malaria itself can cause impaired consciousness, hypoglycemia should be considered and assessed promptly in patients with neurological deterioration.

Malaria During Pregnancy

Malaria during pregnancy is a major medical concern.

Pregnant women are at increased risk of complications from malaria, and infection can adversely affect both mother and fetus.

Potential consequences include maternal anemia and adverse pregnancy outcomes such as premature delivery and low birth weight.

The treatment and prevention of malaria during pregnancy require careful selection of medicines according to parasite species, local resistance patterns, pregnancy stage, and current clinical guidelines.

Pregnant women with fever in malaria-endemic regions should receive prompt medical assessment.

Malaria in Children

Children, particularly those under five years of age, are among the groups at greatest risk of severe malaria.

Children may deteriorate rapidly once severe disease develops.

Severe anemia, respiratory distress, hypoglycemia, seizures, and cerebral malaria are important complications.

Young children may not be able to communicate symptoms clearly, making careful clinical observation particularly important.

In high-transmission settings, partial immunity develops gradually with repeated exposure, but young children remain especially vulnerable before sufficient protection develops.

Malaria in Travelers

Travelers from non-endemic areas may be at increased risk of severe malaria because they generally lack acquired immunity.

A traveler who develops fever after returning from a malaria-endemic area should be evaluated promptly.

Malaria should remain in the differential diagnosis even if the traveler used preventive medication because prophylaxis does not provide absolute protection.

Some malaria infections can also present after a significant delay.

Healthcare providers should therefore obtain a detailed travel history, including destinations and dates of travel.

Diagnosis of Malaria

Laboratory diagnosis is essential for confirming malaria.

Clinical symptoms alone cannot reliably distinguish malaria from many other causes of fever.

The major diagnostic methods include:

Microscopic examination of blood smears
Rapid diagnostic tests
Molecular tests such as nucleic acid amplification tests in appropriate settings

WHO recommends parasite-based confirmation of suspected malaria through microscopy or rapid diagnostic testing.

Urgent diagnosis is particularly important because malaria can progress rapidly.

Blood Smear Examination

Microscopic examination of blood remains a fundamental diagnostic method.

Both thick and thin blood smears can be used.

Thick smears are highly useful for detecting parasites because a larger volume of blood is examined.

Thin smears help identify the Plasmodium species and estimate parasite density.

Microscopy can therefore provide information that is important for both diagnosis and treatment planning.

Repeated blood smears may sometimes be necessary when the initial examination is negative but clinical suspicion remains high.

Rapid Diagnostic Tests

Rapid diagnostic tests detect malaria parasite antigens in a blood sample.

They can provide results more quickly than conventional microscopy and are particularly useful where trained microscopy personnel are not readily available.

However, rapid tests have limitations.

Some tests detect specific parasite proteins, and genetic changes in parasites can sometimes affect the performance of certain antigen-based tests.

Therefore, rapid diagnostic tests should be interpreted according to the specific test characteristics and local epidemiology.

Where available and appropriate, microscopy remains important for confirming infection, identifying the species, and estimating parasite density.

Molecular Diagnosis

Molecular techniques can detect Plasmodium DNA or RNA with high sensitivity.

Nucleic acid amplification tests can be particularly useful for identifying species and mixed infections.

However, molecular testing may not always be immediately available in every healthcare setting.

Because malaria can deteriorate quickly, diagnostic methods that provide timely results are essential.

Molecular testing may therefore complement rather than replace rapid diagnostic tests and microscopy, depending on the clinical environment.

Laboratory Findings in Malaria

Several laboratory abnormalities may occur during malaria infection.

Common findings include:

Anemia
Thrombocytopenia
Increased bilirubin
Elevated liver enzymes
Elevated lactate in severe disease
Abnormal renal function
Electrolyte abnormalities
Hypoglycemia

The severity of these abnormalities varies according to the parasite species and clinical severity.

Laboratory investigations are also important for detecting complications and monitoring response to treatment.

Parasite Density

Parasite density refers to the proportion or number of infected red blood cells or parasites detected in the blood.

Determining parasite density is particularly important in P. falciparum infection because a high parasite burden is associated with severe disease.

Serial parasite measurements can also help clinicians evaluate the response to therapy.

Persistent or increasing parasitemia may suggest treatment failure, drug resistance, inadequate drug exposure, incorrect diagnosis, or another clinical problem.

Differential Diagnosis of Malaria

Malaria shares symptoms with numerous infectious and non-infectious diseases.

The differential diagnosis may include:

Dengue fever
Typhoid fever
Viral infections
Influenza
COVID-19
Chikungunya
Sepsis
Meningitis
Encephalitis
Leptospirosis
Brucellosis
Acute bacterial infections

In regions where malaria is common, clinicians must avoid assuming that every fever is malaria.

Conversely, in regions where malaria is uncommon, clinicians must not overlook malaria in patients with a relevant travel or exposure history.

Laboratory confirmation is therefore extremely important.

Treatment of Malaria

Malaria is treatable and curable when appropriate therapy is started promptly.

The treatment regimen depends on several factors, including:

Plasmodium species
Geographic location where infection was acquired
Local antimalarial resistance patterns
Disease severity
Age and body weight
Pregnancy status
Previous antimalarial exposure
Ability to tolerate oral medication

WHO identifies artemisinin-based combination therapies as the most effective treatments for P. falciparum malaria.

Treatment should be selected according to current local and international guidelines rather than using the same drug regimen for every patient.

Treatment of Uncomplicated Malaria

Uncomplicated malaria can generally be treated with oral antimalarial medication when the patient is clinically stable and able to tolerate oral therapy.

Artemisinin-based combination therapies are widely used, particularly for P. falciparum infections.

The exact drug combination and treatment duration depend on the parasite species and local resistance patterns.

For example, current CDC guidance in the United States has specific recommendations based on the geographic origin of infection, and as of 2026 it recommends a five-day artemether-lumefantrine regimen for uncomplicated P. falciparum infection in that setting. Treatment recommendations can differ between countries, so clinicians should follow the applicable current guideline.

Treatment of Plasmodium vivax

P. vivax requires particular attention because it can produce both blood-stage infection and dormant liver-stage infection.

Treatment therefore has two objectives:

Eliminate the parasites in the bloodstream.
Eliminate dormant liver-stage parasites to prevent relapse.

Chloroquine may be appropriate for P. vivax in locations where the parasite remains sensitive to it.

However, drug resistance is an important consideration.

Anti-relapse therapy with an appropriate drug is required when treatment of dormant liver stages is indicated.

Before certain anti-relapse medicines are used, evaluation for glucose-6-phosphate dehydrogenase deficiency may be necessary because some drugs can cause hemolysis in susceptible individuals.

Treatment of Plasmodium ovale

P. ovale can also form dormant liver-stage parasites.

Consequently, treatment generally requires therapy directed at both the blood-stage infection and the dormant liver-stage parasites.

The choice of medication depends on clinical circumstances, geographic origin, drug resistance, and the patient's suitability for anti-relapse therapy.

As with P. vivax, assessment for G6PD deficiency is important before using certain medications for radical cure.

Treatment of Severe Malaria

Severe malaria requires immediate hospital treatment.

Intravenous artesunate is a key treatment for severe malaria.

Treatment should not be delayed when severe malaria is strongly suspected and appropriate emergency management is available.

Supportive treatment is equally important.

Patients may require management of:

Hypoglycemia
Severe anemia
Respiratory failure
Acute kidney injury
Shock
Seizures
Acidosis
Electrolyte abnormalities
Fluid disturbances

Patients with severe malaria require close monitoring because organ dysfunction can progress rapidly.

Current clinical guidance emphasizes urgent diagnosis and immediate treatment because severe malaria can become fatal without prompt intervention.

Antimalarial Drug Resistance

Antimalarial drug resistance is a major challenge in malaria control.

Parasites can develop genetic changes that reduce their sensitivity to antimalarial medications.

Resistance to older drugs has occurred in many regions, and partial resistance to artemisinin derivatives has been documented in several locations.

Because resistance patterns differ geographically, treatment recommendations must take local resistance into account.

Inappropriate use of antimalarial drugs, incomplete treatment courses, poor-quality medicines, and inadequate drug exposure can contribute to the emergence and spread of resistance.

WHO continues to monitor antimalarial drug resistance globally.

Prevention of Malaria

Preventing malaria requires reducing mosquito exposure, reducing transmission, and protecting vulnerable populations.

Important preventive strategies include:

Insecticide-treated mosquito nets
Indoor residual spraying
Appropriate clothing
Mosquito repellents
Reduction of mosquito breeding sites
Chemoprevention when indicated
Vaccination programs where recommended

No single preventive measure provides complete protection in every situation.

The most effective malaria-control programs combine several approaches according to local transmission patterns.

Insecticide-Treated Mosquito Nets

Insecticide-treated mosquito nets are an important malaria-prevention tool.

They reduce the likelihood of mosquitoes biting people while they sleep.

Nets are particularly valuable because many malaria-transmitting mosquitoes feed during nighttime hours.

Regular and correct use can reduce exposure to infectious mosquito bites.

Community-wide distribution programs can provide substantial benefits in areas with high malaria transmission.

Indoor Residual Spraying

Indoor residual spraying involves applying approved insecticides to the interior walls of buildings.

When mosquitoes rest on treated surfaces, the insecticide can kill them or reduce their ability to transmit malaria.

The effectiveness of indoor residual spraying depends on mosquito behavior, insecticide susceptibility, coverage, and implementation quality.

Insecticide resistance among mosquito populations is an increasing challenge and requires surveillance and appropriate selection of control strategies.

Personal Protection Against Mosquito Bites

Individuals can reduce mosquito exposure through several practical measures.

These include sleeping under insecticide-treated nets, using appropriate mosquito repellents, wearing clothing that reduces exposed skin, and using screens or other physical barriers where available.

Air conditioning can also reduce mosquito exposure in appropriate settings.

Travelers to malaria-endemic regions should obtain destination-specific medical advice before travel because malaria risk and recommended preventive medication differ by location.

Chemoprevention of Malaria

Chemoprevention involves taking antimalarial medication to reduce the risk of malaria infection or severe disease in appropriate populations.

Different preventive regimens are used for travelers, pregnant women, children, and populations living in high-transmission areas.

The correct medication depends on geographic location, parasite resistance, age, pregnancy status, medical history, and other factors.

Preventive medication should not be selected solely on the basis of a general malaria label because resistance patterns differ between regions.

Malaria Vaccines

Malaria vaccination has become an important component of malaria-control strategies.

WHO recommends malaria vaccines for prevention of P. falciparum malaria in children living in malaria-endemic areas, as part of a broader malaria-control strategy.

Vaccination does not replace mosquito-control measures, prompt diagnosis, or effective treatment.

Instead, vaccination can complement other malaria interventions.

Implementation depends on national policies, disease burden, vaccine availability, and public-health priorities.

Malaria and Public Health

Malaria is not only an individual medical problem but also a major public-health challenge.

Transmission is influenced by environmental conditions, healthcare access, poverty, housing quality, mosquito-control infrastructure, availability of diagnostic testing, and access to effective medicines.

Reducing malaria therefore requires cooperation between healthcare workers, laboratories, public-health authorities, communities, and international organizations.

Surveillance systems help identify changes in malaria incidence, parasite species, drug resistance, mosquito behavior, and transmission patterns.

Complications of Malaria

Malaria can produce complications affecting almost every major organ system.

Important complications include:

Severe anemia
Cerebral malaria
Seizures
Coma
Acute kidney injury
Pulmonary edema
Acute respiratory distress
Hypoglycemia
Metabolic acidosis
Jaundice
Shock
Abnormal bleeding
Multiple-organ failure

The risk of complications increases when diagnosis and treatment are delayed.

Some complications develop rapidly, especially in P. falciparum infection.

Prognosis of Malaria

The prognosis depends on the parasite species, severity of infection, immune status, age, pregnancy status, access to healthcare, and speed of diagnosis and treatment.

Uncomplicated malaria is generally curable when diagnosed and treated appropriately.

Severe malaria can be fatal, particularly when treatment is delayed.

Early recognition and appropriate antimalarial therapy significantly improve outcomes.

Patients who recover from malaria may still require follow-up in certain circumstances, particularly when they have infections capable of relapse or when significant organ complications occurred.

Importance of Early Diagnosis

Early diagnosis is one of the most important factors influencing malaria outcomes.

Because initial symptoms may be mild and nonspecific, patients may delay seeking care.

This is especially dangerous with P. falciparum infection because severe disease can develop rapidly.

Healthcare providers should maintain a high level of suspicion in febrile patients with recent exposure to malaria-endemic areas.

Prompt laboratory testing allows appropriate treatment to begin before severe complications develop.

When Malaria Requires Emergency Care

Certain symptoms should be considered medical emergencies in a patient with suspected or confirmed malaria.

These include:

Altered consciousness
Seizures
Difficulty breathing
Severe weakness or prostration
Severe anemia
Reduced urine output
Shock
Persistent vomiting
Jaundice with other severe features
Abnormal bleeding
Severe hypoglycemia
Coma

These findings may indicate severe malaria and require immediate hospital treatment.

Malaria should never be allowed to progress untreated simply because the initial fever appears mild.

Follow-Up After Malaria Treatment

Follow-up depends on the parasite species, treatment used, disease severity, and clinical response.

Patients treated for P. falciparum may require assessment to ensure parasitemia has cleared and that complications have resolved.

Patients with P. vivax or P. ovale require particular attention to relapse prevention because dormant liver-stage parasites can reactivate.

Patients who continue to experience fever after treatment require reassessment.

Persistent symptoms may indicate treatment failure, drug resistance, reinfection, relapse, an incorrect diagnosis, or another concurrent illness.

Malaria and Drug Adherence

Completing the prescribed antimalarial regimen is extremely important.

Stopping treatment early may allow surviving parasites to multiply again.

Incomplete therapy can contribute to treatment failure and may contribute to the development and spread of drug resistance.

Patients should take antimalarial medicines exactly as prescribed and should contact a healthcare professional if vomiting, adverse effects, or other problems prevent them from completing treatment.

Medication should not be shared with other people because malaria treatment must be selected according to the patient's specific infection and clinical circumstances.

Malaria and Reinfection

A person who has recovered from malaria can become infected again.

Previous infection does not necessarily provide complete lifelong protection.

In endemic regions, repeated exposure can produce partial immunity, which may reduce the risk of severe disease without completely preventing infection.

Therefore, individuals who have previously had malaria should continue to use preventive measures.

A new episode of fever after recovery should not automatically be assumed to represent the previous infection; reinfection, relapse, and other illnesses may all need consideration.

Malaria and Relapse

Relapse is particularly associated with P. vivax and P. ovale.

These parasites can establish dormant liver-stage forms.

The parasites can remain inactive for a period before reactivating and producing another blood-stage infection.

A patient may therefore develop malaria symptoms again after apparently successful treatment.

Preventing relapse requires appropriate treatment of the dormant liver stages in patients who are suitable for such therapy.

This is one reason why identifying the parasite species is clinically important.

Malaria and Recrudescence

Recrudescence differs from relapse.

Recrudescence occurs when blood-stage parasites are not completely eliminated and later increase again to clinically significant levels.

It may occur because of inadequate drug exposure, incomplete treatment, drug resistance, or other factors.

Recrudescence is particularly relevant when evaluating recurrent malaria after treatment.

Distinguishing relapse, recrudescence, and reinfection may require careful assessment of parasite species, treatment history, geographic exposure, and laboratory findings.

Malaria Control Strategies

Successful malaria control requires multiple coordinated interventions.